share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  08/08 08:34
Moomoo AI 已提取核心信息
On August 7, 2024, Conduit Pharmaceuticals Inc. entered into a License Agreement with AstraZeneca AB, granting Conduit exclusive rights to develop and commercialize certain intellectual property for HK-4 Glucokinase activators and a myeloperoxidase inhibitor for idiopathic male infertility. The agreement includes an upfront payment of $1.5 million, common stock issuance, and tiered sublicense revenue sharing. Conduit will initiate Phase II clinical trials for the licensed compounds, which have already shown favorable preclinical and Phase I data. Additionally, Conduit amended a previous funding agreement with St George Street Capital, allowing for other third-party project funders. The License and Issuance Agreements will be filed with the SEC as part of Conduit's Quarterly Report for Q3 2024.
On August 7, 2024, Conduit Pharmaceuticals Inc. entered into a License Agreement with AstraZeneca AB, granting Conduit exclusive rights to develop and commercialize certain intellectual property for HK-4 Glucokinase activators and a myeloperoxidase inhibitor for idiopathic male infertility. The agreement includes an upfront payment of $1.5 million, common stock issuance, and tiered sublicense revenue sharing. Conduit will initiate Phase II clinical trials for the licensed compounds, which have already shown favorable preclinical and Phase I data. Additionally, Conduit amended a previous funding agreement with St George Street Capital, allowing for other third-party project funders. The License and Issuance Agreements will be filed with the SEC as part of Conduit's Quarterly Report for Q3 2024.
2024年8月7日,Conduit Pharmaceuticals Inc.与阿斯利康Ab签署了一份许可协议,授予Conduit独家开发和商业化Hk-4葡萄糖激酶激动剂和用于特发性男性不育症的髓过氧化物酶抑制剂的某些知识产权的专有权利。该协议包括提前支付150万美元、普通股发行和分层转让收益共享。Conduit将启动已经展示了有利的临床前和I期数据的许可化合物的II期临床试验。此外,Conduit修改了之前与St George Street Capital的资金协议,允许其他第三方项目出资者。许可和发行协议将作为Conduit的2024年第三季度报告的一部分提交给美国证券交易委员会。
2024年8月7日,Conduit Pharmaceuticals Inc.与阿斯利康Ab签署了一份许可协议,授予Conduit独家开发和商业化Hk-4葡萄糖激酶激动剂和用于特发性男性不育症的髓过氧化物酶抑制剂的某些知识产权的专有权利。该协议包括提前支付150万美元、普通股发行和分层转让收益共享。Conduit将启动已经展示了有利的临床前和I期数据的许可化合物的II期临床试验。此外,Conduit修改了之前与St George Street Capital的资金协议,允许其他第三方项目出资者。许可和发行协议将作为Conduit的2024年第三季度报告的一部分提交给美国证券交易委员会。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息